... for advanced penile cancer, including chemotherapy, immunotherapy, and targeted therapy, as well as emerging treatment strategies. Summary: Cisplatin-based chemotherapy is the established first-line treatment for advanced penile cancer, but its efficacy is often limited and short-lived. Immune checkpoint...

... to in the content or advertisements. 2025 Liquid biopsy Targeted therapy Personalized medicine Metastatic breast cancer In recent decades, we have witnessed a paradigm shift in the treatment of breast cancer. Initially, breast cancer was treated radically with debilitating surgery as all cancer...

..., instructions or products referred to in the content or advertisements. 2025 Association of Internal Oncology European Society of Medical Oncology Translational oncology Molecular oncology Targeted therapy Immunotherapy Historically, drug approvals predominantly relied on tissue-specific...

... or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2024 AIO ESMO Thoracic oncology Lung cancer Non-small cell lung cancer NSCLC Targeted therapy The European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona...

.... Despite the rapid advancement of targeted therapies and the implementation of treatment escalation through combination strategies, there remains an ongoing debate regarding which patients would benefit most from combination therapies, both in the initial treatment phase and in the setting of disease...

..., instructions or products referred to in the content or advertisements. 2024 ESMO Thoracic oncology Lung cancer Non-small cell lung cancer Targeted therapy The 2023 European Society for Medical Oncology (ESMO) annual meeting was held in Madrid, Spain, from 20 to 24 October bringing together...

... or advertisements. 2022 Metastatic breast cancer Bevacizumab Chemotherapy Targeted therapy Meta-analysis Breast cancer has the leading cause of cancer incidence among female malignancies, with an estimated 2.3 million new cases worldwide in 2020 [ 1 ]. Approximately 20–30% of early breast...

..., resulting in 7 months of progression-free survival (PFS). Triple-negative breast cancer BRAF V600E Heterogeneous Resistance Targeted therapy Next-generation sequencing analysis of the primary tumor revealed a BRAF V600E mutation and other mutations without specific targeted therapy (Fig.  1...

... landscape of CCAs have created opportunities for targeted therapy. Yet, data regarding its efficacy are scarce. We aimed to describe the genomic landscape of a CCA patient cohort using next-generation sequencing (NGS), focusing on the ERBB/EFGR pathway and assessing response to anti-HER2 agents. Methods...

... of action after anti-VEGFR-targeted therapy to a mammalian target of rapamycin inhibitor. 26 06 2018 4 10 2018 19 01 2019 © 2019 S. Karger AG, Basel Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages...

...Keren Rouvinov; Wilmosh Mermershtain; Hadas Dresler; Samuel Ariad; Reut Riff; Noa Shani-Shrem; Daniel Keizman; Amos Douvdevani Summary Background: Limited data about biomarkers are available to predict the outcomes of targeted therapy in metastatic renal cell carcinoma (mRCC). Circulating cell-free...

...Kristina Buder-Bakhaya; Devayani Machiraju; Jessica C. Hassel Summary Treatment of metastatic melanoma has undergone tremendous changes over the past few years. There are now highly effective systemic therapies available: targeted therapy with BRAF and MEK inhibitors in BRAF-V600-mutant melanoma...

.... Breast cancer Young age Targeted therapy Review Article Oncol Res Treat 2016;39:122 128 DOI: 10.1159/000444355 Received: December 08, 2016 Accepted: January 29, 2016 Published online: February 24, 2016 Treatment Modi cation in Young Breast Cancer Patients Anton Scharla Annette Salterbergb Michael...

..., was not improved by the addition of BEV to neoadjuvant chemotherapy [ 9 ]. Therefore, the addition of BEV to standard neoadjuvant chemotherapy cannot be recommended. Breast cancer HER2 negative Targeted therapy Endocrine resistance In breast cancer, important steps have been made towards...

... Lung cancer Next generation sequencing Targeted therapy Epidermal growth factor receptor Gefitinib Lung cancer is the most important cause of cancer-related death [ 1 ]. Approximately 70% of patients with lung cancer have metastatic disease at the time of diagnosis. Many of these patients...